article thumbnail

California’s low-cost insulin plans receive $100m manufacturing boost

Pharmaceutical Technology

Insulin prices made the headlines again as California governor Gavin Newsom announced plans on 7 July for the state to manufacture low-cost insulin. The state plans to work directly with a contract manufacturing organization (CMO) to manufacture low-cost insulin. In-house manufacturing the norm.

article thumbnail

Pharma manufacturing can digitalise its way round the next crisis

pharmaphorum

The turbulence of the last three years can make it seem as though pharma manufacturers have been operating in an atmosphere of non-stop crisis. The net effect has been to stimulate change in every aspect of the pharma industry – an industry not exactly known for its embrace of manufacturing innovation.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

Biden proposes subsidizing drug middlemen for insulin

World of DTC Marketing

Under the bill proposed, Medicare beneficiaries and those insured through private plans would pay no more than $35 for a 30-day insulin prescription, or the lesser of $35 or 25% of the plan’s negotiated price for a 30-day prescription. He says that there are a limited number of manufactures in the U.S., billion to $5.7

Insurance 240
article thumbnail

Why script-to-dispense conversion will take centre stage in 2023

pharmaphorum

In 2023, expect manufacturers to further shift their focus away from acquiring new patient prescriptions to retaining existing customers. The account carried an official blue check mark, but in fact it did not belong to the prescription drugmaker. in 1979 to 2.8%in Ensuring patient access.

article thumbnail

Weathering the good and the bad: Why good business practices work

MedCity News

On the micro level, it’s more prescriptive (i.e., regulatory best practices or good manufacturing practices). For most companies and medtech, in particular, good business practices (GBP) happens on multiple levels. On the macro level, it’s expressed as a set of ethics and principles that govern a company’s conduct.

Ethics 124
article thumbnail

Should we be worried about pharma’s supply chain?

World of DTC Marketing

Pharmaceutical manufacturers and distributors work together in a robust system to deliver high-quality products, but drug manufacturing and distribution have become increasingly complex in recent years. The answer lies in both an outdated way we develop prescription drugs and the continued quest for the next big blockbuster.

article thumbnail

When Will Payers Improve Coverage of Prescription Digital Therapeutics?

PharmExec

Here’s what manufacturers need to know. New MMIT research highlights payers’ continued hesitancy toward PDTs.